import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "pinealon-neuropeptide-bioregulator-research-guide",
  title: "Pinealon: The Pineal Neuropeptide Bioregulator — Preclinical Research Review",
  description:
    "A research-focused guide to Pinealon (Ala-Glu-Asp-Gly), a synthetic tetrapeptide derived from the pineal gland. Covers mechanism, neuroprotective preclinical data, cognitive and circadian endpoints, and protocol considerations for researchers.",
  category: "Compound Profiles",
  readMinutes: 9,
  publishedAt: "2026-06-18",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Pinealon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG) and a molecular weight of approximately 402.4 g/mol. It belongs to a class of short regulatory peptides — often called peptide bioregulators or cytomedins — that were originally isolated from animal tissue extracts by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology during the 1970s through 1990s. Pinealon's parent tissue is the pineal gland, and its preclinical research profile has focused primarily on neuroprotection, circadian rhythm modulation, and cognitive endpoints in aged or stress-exposed animal models.",
    },
    {
      type: "paragraph",
      text: "Unlike pineal gland extract preparations such as Epithalamin, Pinealon is a defined synthetic compound — a critical distinction for researchers who need reproducibility and known purity. It is commercially available as the synthetic AEDG tetrapeptide and is studied via intranasal and subcutaneous routes in animal models.",
    },
    {
      type: "heading",
      text: "Chemistry and Structural Properties",
    },
    {
      type: "paragraph",
      text: "Pinealon (AEDG) consists of four amino acid residues: alanine (Ala), glutamic acid (Glu), aspartic acid (Asp), and glycine (Gly). Its compact tetrapeptide structure enables good CNS penetration, particularly via intranasal administration, which bypasses the blood-brain barrier by utilizing the olfactory-trigeminal pathway. This route is well-established for peptide delivery to brain tissue in rodent models and has been explored in several Pinealon studies as the primary administration method.",
    },
    {
      type: "list",
      items: [
        "Sequence: Ala-Glu-Asp-Gly (AEDG)",
        "Molecular weight: ~402.4 g/mol",
        "Naturally derived from: pineal gland (bovine source in original isolation)",
        "Synthesis: solid-phase peptide synthesis (SPPS)",
        "Primary research routes: intranasal, subcutaneous",
      ],
    },
    {
      type: "heading",
      text: "Proposed Mechanisms of Action",
    },
    {
      type: "subheading",
      text: "Epigenetic Gene Regulation",
    },
    {
      type: "paragraph",
      text: "Khavinson and colleagues have proposed that short peptide bioregulators, including Pinealon, exert their effects through direct DNA binding and epigenetic modulation rather than receptor activation. Molecular modeling studies suggest that AEDG can interact with promoter regions of specific genes — particularly those involved in antioxidant defense (SOD, catalase) and neuroprotection — by binding to the major groove of double-stranded DNA and altering transcription factor accessibility. This mode of action has been described as a form of 'epigenetic programming' at doses too low to saturate receptor systems.",
    },
    {
      type: "subheading",
      text: "Antioxidant Upregulation",
    },
    {
      type: "paragraph",
      text: "Preclinical data from Khavinson's group and collaborating Russian institutes has documented that Pinealon significantly increases activity of superoxide dismutase (SOD) and catalase in brain tissue of aged rats. In one study comparing young vs. old Wistar rats, AEDG administration restored antioxidant enzyme activity in the hippocampus and cerebral cortex to levels approaching those seen in young controls. This antioxidant effect is thought to underlie the neuroprotective outcomes observed in ischemia and oxidative stress models.",
    },
    {
      type: "subheading",
      text: "Neuronal Survival and Anti-Apoptotic Effects",
    },
    {
      type: "paragraph",
      text: "Pinealon has been studied in primary neuronal cell cultures exposed to oxidative stress (H₂O₂) and calcium ionophore-induced excitotoxicity. Published data showed that AEDG pre-treatment significantly reduced caspase-3 activation and improved neuronal survival compared to vehicle controls. The proposed mechanism involves Bcl-2 upregulation and inhibition of the mitochondrial apoptosis pathway, consistent with the antioxidant enzyme data and DNA-binding gene regulation hypothesis.",
    },
    {
      type: "subheading",
      text: "Melatonin System Interaction",
    },
    {
      type: "paragraph",
      text: "Given its pineal gland origin, Pinealon has been examined for effects on melatonin synthesis pathways. Preclinical data from aged rat models suggests that AEDG administration partially restores arylalkylamine N-acetyltransferase (AANAT) activity — the rate-limiting enzyme in melatonin biosynthesis. Age-related decline in pineal AANAT activity and melatonin production is well-documented, and restoration of this pathway may contribute to Pinealon's observed effects on sleep architecture and circadian rhythm parameters in rodent models.",
    },
    {
      type: "heading",
      text: "Preclinical Study Data: Key Findings",
    },
    {
      type: "subheading",
      text: "Cerebral Ischemia and Neuroprotection",
    },
    {
      type: "paragraph",
      text: "In a widely cited study (Khavinson et al., Bulletin of Experimental Biology and Medicine), rats subjected to bilateral carotid occlusion (a model of global cerebral ischemia) were treated with intranasal Pinealon (0.1 µg/kg/day) beginning 48 hours post-ischemia. The AEDG group showed significantly reduced neuronal death in the hippocampal CA1 region compared to vehicle controls at 7 and 14 days post-occlusion. Neurological deficit scores were also improved, as was performance on Morris water maze testing in surviving animals. The study attributed these outcomes to the antioxidant and anti-apoptotic mechanisms described above.",
    },
    {
      type: "subheading",
      text: "Aging and Cognitive Decline",
    },
    {
      type: "paragraph",
      text: "In naturally aged rats (22–24 months), Pinealon administration over 10 days significantly improved learning and memory performance on maze tasks compared to saline controls. Histological analysis showed increased density of hippocampal neurons in the AEDG group, suggesting reduced age-related neuronal loss. Accompanying biochemical data showed elevated brain-derived neurotrophic factor (BDNF) mRNA levels in the hippocampus — consistent with a role in supporting neuroplasticity in aged tissue.",
    },
    {
      type: "subheading",
      text: "Oxidative Stress and Retinal Protection",
    },
    {
      type: "paragraph",
      text: "A separate line of research has examined Pinealon's effects in the retina, particularly in models of light-induced photoreceptor damage and age-related retinal degeneration. Studies from Kozhukh et al. demonstrated that AEDG intranasal administration reduced photoreceptor apoptosis in light-exposed albino rats, with significantly lower TUNEL-positive cell counts in the outer nuclear layer compared to controls. Retinal SOD activity was significantly higher in treated animals, supporting the antioxidant mechanism hypothesis in ocular tissue as well.",
    },
    {
      type: "subheading",
      text: "Cardiovascular and Diabetes-Related Models",
    },
    {
      type: "paragraph",
      text: "Pinealon has also been studied in streptozotocin-induced diabetic rats, a model associated with both peripheral and central oxidative stress. Published data showed that AEDG partially reversed diabetes-induced reductions in antioxidant enzyme activity in cardiac tissue and improved endothelial function markers in treated animals compared to untreated diabetic controls. These findings suggest the compound's antioxidant effects are not CNS-limited.",
    },
    {
      type: "heading",
      text: "Protocol Design Considerations",
    },
    {
      type: "subheading",
      text: "Dose Ranges Used in Preclinical Studies",
    },
    {
      type: "paragraph",
      text: "The majority of Pinealon studies have used remarkably low doses, consistent with the bioregulator class generally. Intranasal doses in rodent models have ranged from 0.1 to 10 µg/kg per day, with most efficacy data clustered at the lower end (0.1–1 µg/kg). Subcutaneous doses in published protocols have ranged from 1 to 100 µg/kg. Unlike peptides that operate through saturable receptor kinetics, bioregulators are thought to show flat or non-linear dose-response curves — meaning higher is not necessarily better.",
    },
    {
      type: "subheading",
      text: "Administration Route",
    },
    {
      type: "paragraph",
      text: "Intranasal delivery is the most commonly used route in Pinealon CNS research, and for good reason: the tetrapeptide is small enough to traverse the olfactory epithelium and reach brain tissue within minutes. This bypasses both peripheral degradation and the blood-brain barrier. Researchers using SC administration for systemic endpoints (e.g., cardiac or retinal tissue) have reported good bioavailability. Subcutaneous injection in isotonic saline is standard for peripheral endpoints.",
    },
    {
      type: "subheading",
      text: "Study Duration",
    },
    {
      type: "paragraph",
      text: "Most published protocols run 10–30 days. Some aging studies use 10-day cycles repeated across months to assess cumulative effects on longevity endpoints. The short cycle format reflects the bioregulator theory that periodic short-course administration can 'reset' gene expression patterns without tachyphylaxis — a property attributed to epigenetic rather than receptor-mediated mechanisms.",
    },
    {
      type: "heading",
      text: "Comparison with Related Compounds",
    },
    {
      type: "table",
      headers: ["Compound", "Sequence", "Origin Tissue", "Primary Research Focus", "Key Distinction"],
      rows: [
        ["Pinealon (AEDG)", "Ala-Glu-Asp-Gly", "Pineal gland", "Neuroprotection, circadian, aging", "Defined synthetic tetrapeptide"],
        ["Epithalon (AEDG-amide)", "Ala-Glu-Asp-Gly-amide", "Pineal gland extract", "Telomere elongation, longevity", "C-terminal amide; different pharma profile"],
        ["Cortagen", "Ala-Glu-Asp-Pro", "Cerebral cortex", "Cognition, cortical neuroprotection", "Different 4th residue (Pro vs Gly)"],
        ["Semax", "MEHFPGP", "ACTH fragment", "BDNF, cognition, neuroprotection", "Unrelated sequence; ACTH-derived"],
      ],
    },
    {
      type: "paragraph",
      text: "Pinealon is often confused with Epithalon (Epitalon) due to their shared pineal origin. They are distinct compounds: Epithalon has a C-terminal amide modification (AEDG-amide vs. AEDG), different physicochemical properties, and a different primary research focus (telomere biology vs. acute neuroprotection). They are not interchangeable and should not be treated as synonyms.",
    },
    {
      type: "heading",
      text: "Sourcing and Purity Standards",
    },
    {
      type: "paragraph",
      text: "As a short tetrapeptide, Pinealon is within the synthesis capability of most reputable SPPS facilities. However, the extremely low research doses used in published studies make purity and accurate concentration critical — small percentage differences in purity compound significantly when working at sub-microgram doses. Researchers should require HPLC purity ≥98% and mass spectrometry confirmation of molecular weight before using any batch in endpoint-driven experiments.",
    },
    {
      type: "callout",
      text: "All research is conducted in preclinical animal models or in vitro systems. Pinealon is not approved for human therapeutic use in any jurisdiction. All compound handling should follow applicable institutional and regulatory guidelines.",
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "Pinealon (AEDG) is a well-characterized synthetic tetrapeptide bioregulator with a focused preclinical research profile in neuroprotection, antioxidant enzyme modulation, and age-related cognitive decline. Its CNS accessibility via intranasal administration, extremely low effective doses, and mechanistic evidence in ischemia and aging models make it a distinctive compound in the bioregulator class. The epigenetic gene regulation hypothesis remains the leading explanatory framework, though receptor-mediated mechanisms have not been fully excluded. Researchers studying neurodegeneration, circadian biology, or aging endpoints will find an unusually consistent body of preclinical data supporting its further investigation.",
    },
    {
      type: "disclaimer",
      text: "This article is for informational and educational purposes only. Pinealon is a research compound not approved for human therapeutic use. All information presented reflects preclinical animal or in vitro research and should not be interpreted as medical advice or clinical guidance.",
    },
  ],
};
